Verastem Oncology announced the discontinuation of its RAMP 203 Phase 1/2 clinical trial evaluating avutometinib in combination with LUMAKRAS™ (sotorasib) and defactinib for advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC). The decision follows an interim data evaluation and reflects a shift in focus toward the clinical development of VS-7375, a KRAS G12D (ON/OFF) inhibitor, in advanced NSCLC and other solid tumors. According to the company, RAMP 203 enrolled 66 patients at the recommended Phase 2 dose, with efficacy data showing a 40% overall response rate and a median progression-free survival of 11.1 months among 30 G12C-inhibitor treatment-naïve patients. These results were available as of the November 26, 2025, data cutoff. Verastem also noted ongoing development of avutometinib and defactinib in other indications, including a Phase 3 confirmatory trial in recurrent low-grade serous ovarian cancer and a trial in advanced pancreatic cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251229302295) on December 29, 2025, and is solely responsible for the information contained therein.